Knowledge Hubs
The latest news on genitourinary oncological disease states.
Prostate Cancer Knowledge Hubs
Advertisement
Urothelial Carcinoma Knowledge Hubs
Testicular, Penile, and Rare Malignancies Knowledge Hubs
Roundtable Discussions
The panel concludes with a discussion on the complexities of interpreting ctDNA positivity in earlier-stage bladder cancer.
The panel considers the adoption of bladder-sparing protocols and the potential of biomarkers to guide risk stratification.
The panel debates the management of high-grade T1 bladder cancer with lymphovascular invasion and variant histology.
The panel pivots to complex considerations in bladder cancer treatment, weighing the promise of IO in BCG-naïve patients.
The panel shares how patient lifestyle, bladder symptoms, and other factors influence intravesical therapy selection.
The panel explores the challenges of delivering bladder-sparing therapies like gem/doce and TAR-200 in real-world settings.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, PhDEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.